Cargando…
Camrelizumab-induced anaphylactic shock in an esophageal squamous cell carcinoma patient: A case report and review of literature
BACKGROUND: Camrelizumab (SHR-1210), an immune checkpoint inhibitor, is clinically used as a therapeutic option for various types of tumors. However, reports of adverse reactions associated with camrelizumab are gradually increasing. Anaphylactic shock due to camrelizumab has not been reported previ...
Autores principales: | Liu, Kai, Bao, Jian-Feng, Wang, Tao, Yang, Hao, Xu, Bao-Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254201/ https://www.ncbi.nlm.nih.gov/pubmed/35949858 http://dx.doi.org/10.12998/wjcc.v10.i18.6198 |
Ejemplares similares
-
Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma
por: Chen, Fei, et al.
Publicado: (2022) -
Anaphylactic Shock
por: Ghosh, P. K.
Publicado: (1949) -
Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma
por: Zhang, Wencheng, et al.
Publicado: (2021) -
Sugammadex-induced anaphylactic shock
por: Kim, Ha-Jung, et al.
Publicado: (2020) -
Literature analysis of Acanthopanax anaphylactic shock in China
por: Zhan, Qian
Publicado: (2015)